Latest Issue

Volume 23 Issue 4

Paper of the Month

Possible net harms of breast cancer screening: updated modelling of Forrest report.

Raftery J, M Chorozoglou.
University of Southampton, Southampton, UK.
BMJ 2011;343:1–8.
The Forrest report, published in 1986, analyzed the costs and benefits of mammographic breast screening in terms of quality-adjusted life years (QALYs) and led to the introduction of mammographic screening in the UK (www.cancerscreening.nhs.uk/breastscreen/publications/forrest-report.html). One of the earliest uses of QALYs to guide policy, the report suggested that screening would reduce the breast cancer-related mortality rate by almost one-third with little harm and a low cost. The key data used in the Forrest report were drawn from two randomized trials: the Swedish two counties trial and the Health Insurance Plan New York trial. The Forrest report claimed that overdiagnosis was not a problem based on the New York trial, but noted that the Swedish trial found possible overdiagnosis in 20% of patients. The authors stated that “further follow-up is required to find out whether this excess persisted”.
» Read an expert review of this paper

Webcast

Tamoxifen Use and Second Breast Cancers
Christopher Li, MD PhD, (Associated member, Public Health Sciences Division, Fred Hutchinson Cancer Research Center) discusses tamoxifen use and second breast cancers.

Our most popular articles

Latest news

  • Home
  • Home
  • Home
  • Home
  • Home
  • Home

READER POLL

Breast Cancer Poll 1
What approach do you currently use for the treatment of patients with HER2-overexpressing metastatic breast cancer whose disease has progressed despite trastuzumab?






Powered by NetPolls

READER SURVEY

SUBMIT AN ARTICLE

OTHER REMEDICA JOURNALS

COMPASS PUBMED SEARCH

Enter your search terms below to search pubmed for articles